

We claim:

- 1) A crystalline aripiprazole form III, characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 8.8, 11.2, 11.4, 11.9, 13.6, 14.4, 15.0, 15.9, 16.4, 17.8, 18.7, 20.4, 20.8, 21.4, 22.2, 23.5, 25.0, 25.9 and 26.5 degrees.
5
- 2) A crystalline aripiprazole form III as defined in claim 1, further characterized by an x-ray powder diffraction spectrum as in figure 1.
- 3) A process for preparation of aripiprazole form III as defined in claim 1, which comprises the steps of:
 - 10 a) preparing a solution of aripiprazole in a mixture of methyl tert-butyl ether, acetonitrile and tetrahydrofuran; and
 - b) isolating aripiprazole form III from the solution.
- 4) Aripiprazole methanolate.
- 5) Aripiprazole methanolate of claim 4, wherein methanol content is between
15 about 2 to 6% of the weight of aripiprazole methanolate.
- 6) A crystalline aripiprazole methanolate form IV, characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 9.8, 11.0, 11.8, 12.1, 12.6, 13.6, 17.4, 18.8, 20.1, 23.3, 24.6, 25.0, 25.9, 27.2, 28.4, 29.3, 30.1 and 31.5 degrees.
- 20 7) A crystalline aripiprazole methanolate form IV as defined in claim 6, further characterized by an x-ray powder diffraction spectrum as in figure 2.
- 8) A process for preparation of aripiprazole methanolate as defined in claim 4, which comprises the steps of:
 - 25 a) preparing a solution of aripiprazole in a mixture of methanol and tetrahydrofuran; and
 - b) isolating aripiprazole methanolate from the solution.
- 9) A process according to claim 8, wherein the product obtained is aripiprazole methanolate.
- 10) A process according to claim 3, wherein aripiprazole is used in the form of
30 Aripiprazole methanolate.
- 11) Aripiprazole ethylenedichloride solvate.
- 12) Aripiprazole ethylenedichloride solvate of claim 11, wherein ethylenedichloride content is between about 15 to 40% of the weight of aripiprazole ethylenedichloride solvate.

- 13) A crystalline aripiprazole ethylenedichloride solvate form V, characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 10.7, 17.6, 17.8, 20.6, 22.1, 23.4, 24.7 and 26.4 degrees.
- 14) A crystalline aripiprazole ethylenedichloride solvate form V as defined in claim 13, further characterized by an x-ray powder diffraction spectrum as in figure 3.
- 15) A process for preparation of aripiprazole ethylenedichloride solvate as defined in claim 11, which comprises the steps of:
- a) preparing a solution of aripiprazole in ethylenedichloride; and
 - b) isolating aripiprazole ethylenedichloride solvate from the solution.
- 16) A process according to claim 15, wherein the product obtained is aripiprazole ethylenedichloride form V.
- 17) A process according to claim 3, wherein aripiprazole used is in the form of Aripiprazole ethylenedichloride.
- 18) A pharmaceutical composition comprising aripiprazole form III of claim 1 and a pharmaceutically acceptable carrier or diluent.